Tarsus Pharmaceuticals, Inc. Common Stock
Symbol: TARS (NASDAQ)
Company Description:
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.
- Today's Open: $57.54
- Today's High: $59.413
- Today's Low: $55.961
- Today's Volume: 207.10K
- Yesterday Close: $57.34
- Yesterday High: $59.78
- Yesterday Low: $56.96
- Yesterday Volume: 559.73K
- Last Min Volume: 651
- Last Min High: $59.275
- Last Min Low: $59.229
- Last Min VWAP: $59.23463
- Name: Tarsus Pharmaceuticals, Inc. Common Stock
- Website: https://www.tarsusrx.com
- Listed Date: 2020-10-16
- Location: IRVINE, CA
- Market Status: Active
- CIK Number: 0001819790
- SIC Code: 2836
- SIC description: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
- Market Cap: $2.42B
- Round Lot: 100
- Outstanding Shares: 42.21M
- Asset Type: CS
Filing Date | Filing Type | Format |
---|---|---|
2025-09-26 | 4 | View |
2025-09-24 | 144 | View |
2025-09-18 | 4 | View |
2025-09-16 | 4 | View |
2025-09-10 | 4 | View |
2025-09-08 | 144 | View |
2025-08-14 | SCHEDULE 13G/A | View |
2025-08-13 | 4 | View |
2025-08-11 | 144 | View |
2025-08-06 | 10-Q | View |
2025-08-06 | 8-K | View |
2025-07-28 | SCHEDULE 13G | View |
2025-06-18 | 4 | View |
2025-06-18 | 8-K | View |
2025-06-17 | 144 | View |
2025-06-17 | 4 | View |
2025-06-16 | 4 | View |
2025-06-16 | 4 | View |
2025-06-16 | 4 | View |
2025-06-16 | 4 | View |